# US 2021/0239695 A1 · Immunoreactive polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0239695 A1
- Document ID: US20210239695A1
- Status: Published application
- Kind: A1
- Application number: 17/053,539
- Filed: 2019-05-07
- Published: 2021-08-05
- Earliest claimed: 2018-05-07
- Assignees: Research Development Foundation
- Applicants: Research Development Foundation
- Inventors: Jere MCBRIDE; David H. Walker
- Web page: https://patentgrep.com/patent/US20210239695A1

## CPC

- G01N 33/56911: {Bacteria}
- A61K 31/65: Tetracyclines
- C07K 14/29: from Richettsiales (O)
- G01N 33/54346: {Nanoparticles}
- C07K 2319/21: containing a His-tag
- G01N 2333/29: from Richettsiales (o)
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods and compositions for diagnosing and vaccinating against Ehrlichia chaffeensis are provided.

## Claims

### Claim 1

A method of detecting antibodies that specifically bind an Ehrlichia organism in a test sample, comprising: (a) contacting an isolated polypeptide of Table 1, Table 2, or Table 3 or a polypeptide having at least 95% sequence identity thereto, with the test sample, under conditions that allow peptide-antibody complexes to form; (b) detecting the peptide-antibody complexes; wherein the detection of the peptide-antibody complexes is an indication that antibodies specific for an Ehrlichia organism are present in the test sample, and wherein the absence of the peptide-antibody complexes is an indication that antibodies specific an Ehrlichia organism are not present in the test sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polypeptide is selected from the group consisting of a polypeptide of Table 2.

### Claim 3 (depends on 1)

The method of claim 1, wherein the polypeptide is selected from the group consisting of a polypeptide of Table 3.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the Ehrlichia organism is an Ehrlichia chaffeensis organism.

### Claim 5 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the step of detecting comprises performing an enzyme-linked immunoassay, a radioimmunoassay, an immunoprecipitation, a fluorescence immunoassay, a chemiluminescent assay, an immunoblot assay, a lateral flow assay, a flow cytometry assay, a multiplex immunoassay, a mass spectrometry assay, or a particulate-based assay.

### Claim 6 (depends on 5)

The method of claim 5, wherein the step of detecting comprises a lateral flow assay or an enzyme-linked immunoassay, wherein the enzyme-linked immunoassay is an ELISA.

### Claim 7 (depends on 1, 4, 5, 6)

The method of any one of claim 1 or 4-6, wherein the isolated polypeptide is A77 (SEQ ID NO:22), A62 (SEQ ID NO:17), A56 (SEQ ID NO:16), A19 (SEQ ID NO:6), A50 (Ech_0700; SEQ ID NO: 28), A51 (SEQ ID NO:13), A14 (SEQ ID NO:4), A63 (SEQ ID NO:18), A34 (SEQ ID NO:9), A9 (SEQ ID NO:3), or A42 (Ech_0240; SEQ ID NO:11).

### Claim 8

A method of identifying an Ehrlichia infection in a mammalian subject comprising: (a) contacting a biological sample from the subject with an isolated polypeptide of Table 1, Table 2, or Table 3 under conditions that allow peptide-antibody complexes to form; and (b) detecting the peptide-antibody complexes; wherein the detection of the peptide-antibody complexes is an indication that the subject has an Ehrlichia infection.

### Claim 9 (depends on 8)

The method of claim 8, wherein the polypeptide is selected from the group consisting of Table 2.

### Claim 10 (depends on 8)

The method of claim 8, wherein the polypeptide is selected from the group consisting of Table 3.

### Claim 11 (depends on 8, 9, 10)

The method of any one of claims 8-10, wherein the step of detecting comprises performing an enzyme-linked immunoassay, a radioimmunoassay, an immunoprecipitation, a fluorescence immunoassay, a chemiluminescent assay, an immunoblot assay, a lateral flow assay, a flow cytometry assay, a multiplex immunoassay, a dipstick test, or a particulate-based assay.

### Claim 12 (depends on 8)

The method of claim 8, wherein the subject is a human.

### Claim 13 (depends on 8)

The method of claim 8, wherein the subject is a dog.

### Claim 14 (depends on 8, 11, 12, 13)

The method of any one of claim 8 or 11-13, wherein the isolated polypeptide is A77 (SEQ ID NO:22), A62 (SEQ ID NO:17), A56 (SEQ ID NO:16), A19 (SEQ ID NO:6), A50 (Ech_0700; SEQ ID NO: 28), A51 (SEQ ID NO:13), A14 (SEQ ID NO:4), A63 (SEQ ID NO:18), A34 (SEQ ID NO:9), A9 (SEQ ID NO:3), or A42 (Ech_0240; SEQ ID NO:11).

### Claim 15

An isolated polypeptide comprising a sequence of Table 1, Table 2, or Table 3, wherein the isolated peptide is immobilized on a surface of a support substrate.

### Claim 16 (depends on 15)

The method of claim 15, wherein the polypeptide is selected from the group consisting of Table 2.

### Claim 17 (depends on 15)

The method of claim 15, wherein the polypeptide is selected from the group consisting of Table 3.

### Claim 18 (depends on 15, 16, 17)

The peptide of any one of claims 15-17, wherein the support substrate comprises latex, polystyrene, nylon, nitrocellulose, cellulose, silica, agarose, or magnetic resin.

### Claim 19 (depends on 15, 16, 17, 18)

The peptide of any one of claims 15-18, wherein the support substrate is a reaction chamber, a well, a membrane, a filter, a paper, an emulsion, a bead, a microbead, a dipstick, a card, a glass slide, a lateral flow apparatus, a microchip, a comb, a silica particle, a magnetic particle, a nanoparticle, or a self-assembling monolayer.

### Claim 20 (depends on 15, 16, 17, 18, 19)

The peptide of any one of claims 15-19, wherein the peptide is comprised in a kit.

### Claim 21 (depends on 15, 16, 17, 18, 19)

The peptide of any one of claims 15-19, wherein the peptide is produced via peptide synthesis or in vitro transcription and translation (IVTT).

### Claim 22 (depends on 15, 16, 17, 18, 19)

The peptide of any one of claims 15-19, wherein the peptide is recombinantly produced.

### Claim 23 (depends on 15, 18, 19, 20, 21, 22)

The method of any one of claim 15 or 18-22, wherein the isolated polypeptide is A77 (SEQ ID NO:22), A62 (SEQ ID NO:17), A56 (SEQ ID NO:16), A19 (SEQ ID NO:6), A50 (Ech_0700; SEQ ID NO: 28), A51 (SEQ ID NO:13), A14 (SEQ ID NO:4), A63 (SEQ ID NO:18), A34 (SEQ ID NO:9), A9 (SEQ ID NO:3), or A42 (Ech_0240; SEQ ID NO:11).

### Claim 24

An isolated polypeptide comprising a sequence of Tablet, Table 2, or Table 3, wherein the isolated peptide is covalently attached to a detectable label.

### Claim 25 (depends on 24)

The polypeptide of claim 24, wherein the polypeptide is selected from the group consisting of Table 2.

### Claim 26 (depends on 24)

The polypeptide of claim 24, wherein the polypeptide is selected from the group consisting of Table 3.

### Claim 27 (depends on 24, 25, 26)

The polypeptide of any one of claims 24-26, wherein the detectable label a fluorescent label, a radioactive label, an enzyme label, or a luminescent nanoparticle.

### Claim 28 (depends on 27)

The polypeptide of claim 27, wherein the luminescent nanoparticle is a luminescent rare earth nanoparticle, a luminous nanoparticle, or a strontium aluminate nanoparticle.

### Claim 29 (depends on 24, 25, 26, 27, 28)

The polypeptide of any one of claims 24-28, wherein the polypeptide is comprised in a kit.

### Claim 30 (depends on 24, 25, 26, 27, 28, 29)

The polypeptide of any one of claims 24-29, wherein the polypeptide is produced via peptide synthesis or in vitro transcription and translation (IVTT).

### Claim 31 (depends on 24, 25, 26, 27, 28, 29)

The polypeptide of any one of claims 24-29, wherein the polypeptide is recombinantly produced.

### Claim 32 (depends on 24, 27, 28, 29, 30, 31)

The method of any one of claim 24 or 27-31, wherein the isolated polypeptide comprises or consists of A77 (SEQ ID NO:22), A62 (SEQ ID NO:17), A56 (SEQ ID NO:16), A19 (SEQ ID NO:6), A50 (Ech_0700; SEQ ID NO: 28), A51 (SEQ ID NO:13), A14 (SEQ ID NO:4), A63 (SEQ ID NO:18), A34 (SEQ ID NO:9), A9 (SEQ ID NO:3), or A42 (Ech_0240; SEQ ID NO:11).

### Claim 33 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32)

A kit comprising: (a) the isolated polypeptide of any one of claims 24-32, (b) an anti-dog or anti-human secondary antibody linked to a reporter molecule; and, (c) an appropriate reagent for detection of the reporter molecule.

### Claim 34 (depends on 33)

The kit of claim 33, wherein the peptide is immobilized on a membrane or a microtiter plate.

### Claim 35 (depends on 33, 34)

The kit of any one of claims 33-34, wherein the reporter molecule is selected from the group consisting of luciferase, horseradish peroxidase, a luminous nanoparticle, P-galactosidase, and a fluorescent label.

### Claim 36 (depends on 35)

The kit of claim 35, wherein the luminous nanoparticle is a strontium aluminate nanoparticle.

### Claim 37 (depends on 33, 34, 35, 36)

The kit of claim of any one of claims 33-36, wherein the kit further comprises a dilution buffer for dog or human serum.

### Claim 38 (depends on 33, 34, 35, 36, 37)

The kit of claim of any one of claims 33-37, wherein the kit comprises a lateral flow immunoassay or a lateral flow immunochromatographic assay.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The kit of claim of any one of claims 33-38, wherein the kit comprises an enzyme-linked immunosorbent assay (ELISA).

### Claim 40

A method of inducing an immune response in a mammalian subject comprising administering to the subject an effective amount of a pharmaceutical preparation comprising a polypeptide of Table 1, Table 2, or Table 3.

### Claim 41 (depends on 40)

The method of claim 40, wherein the polypeptide is selected from the group consisting of Table 2 and Table 3.

### Claim 42 (depends on 40, 41)

The method of any one of claims 40-41, wherein the subject is a human.

### Claim 43 (depends on 40, 41, 42)

The method of any one of claims 40-42, wherein the pharmaceutical preparation is administered subcutaneously, intramuscularly, nasally, via inhalation or aerosol delivery, or intradermally.

### Claim 44 (depends on 40, 42, 43)

The method of any one of claim 40 or 42-43, wherein the isolated polypeptide comprises or consists of A77 (SEQ ID NO:22), A62 (SEQ ID NO:17), A56 (SEQ ID NO:16), A19 (SEQ ID NO:6), A50 (Ech_0700; SEQ ID NO: 28), A51 (SEQ ID NO:13), A14 (SEQ ID NO:4), A63 (SEQ ID NO:18), A34 (SEQ ID NO:9), A9 (SEQ ID NO:3), or A42 (Ech_0240; SEQ ID NO:11).

### Claim 45

A method of treating an Ehrlichia chaffeensis infection in a subject comprising:
(a) contacting a biological sample from the subject with an isolated polypeptide of Table 1, Table 2, or Table 3 under conditions that allow peptide-antibody complexes to form;
(b) detecting the peptide-antibody complexes; wherein the detection of the peptide-antibody complexes is an indication that the subject has an Ehrlichia chaffeensis infection; and
(c) administering a therapeutic compound to treat Ehrlichia infection in the subject.

### Claim 46 (depends on 45)

The method of claim 45, wherein the polypeptide is selected from the group consisting of Table 2.

### Claim 47 (depends on 45)

The method of claim 45, wherein the polypeptide is selected from the group consisting of Table 3.

### Claim 48 (depends on 45, 46, 47)

The method of any one of claims 45-47, wherein the step of detecting comprises performing an enzyme-linked immunoassay, a radioimmunoassay, an immunoprecipitation, a fluorescence immunoassay, a chemiluminescent assay, an immunoblot assay, a lateral flow assay, a flow cytometry assay, a multiplex immunoassay, a dipstick test, or a particulate-based assay.

### Claim 49 (depends on 45)

The method of claim 45, wherein the subject is a dog.

### Claim 50 (depends on 45)

The method of claim 45, wherein the subject is a human.

### Claim 51 (depends on 45, 46, 47, 48, 49, 50)

The method of any one of claims 45-50, wherein the therapeutic compound is an antibiotic.

### Claim 52 (depends on 51)

The method of claim 51, wherein the antibiotic is doxycycline.

### Claim 53 (depends on 45, 48, 49, 50, 51, 52)

The method of any one of claim 45 or 48-52, wherein the isolated polypeptide is A77 (SEQ ID NO:22), A62 (SEQ ID NO:17), A56 (SEQ ID NO:16), A19 (SEQ ID NO:6), A50 (Ech_0700; SEQ ID NO: 28), A51 (SEQ ID NO:13), A14 (SEQ ID NO:4), A63 (SEQ ID NO:18), A34 (SEQ ID NO:9), A9 (SEQ ID NO:3), or A42 (Ech_0240; SEQ ID NO:11).

### Claim 54

A method of detecting antibodies that specifically bind an Ehrlichia organism in a test sample, comprising: (a) contacting an isolated polypeptide of: Ecaj_0919, Ecaj_0073, Ecaj_0104, Ecaj_0663, or Ecaj_0881, more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, or Ecaj_0663, even more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, even more preferably Ecaj_0919 or Ecaj_0073; or a polypeptide having at least 95% sequence identity thereto, with the test sample, under conditions that allow peptide-antibody complexes to form; (b) detecting the peptide-antibody complexes; wherein the detection of the peptide-antibody complexes is an indication that antibodies specific for an Ehrlichia organism are present in the test sample, and wherein the absence of the peptide-antibody complexes is an indication that antibodies specific an Ehrlichia organism are not present in the test sample.

### Claim 55 (depends on 54)

The method of claim 54, wherein the step of detecting comprises performing an enzyme-linked immunoassay, a radioimmunoassay, an immunoprecipitation, a fluorescence immunoassay, a chemiluminescent assay, an immunoblot assay, a lateral flow assay, a flow cytometry assay, a multiplex immunoassay, a mass spectrometry assay, or a particulate-based assay.

### Claim 56 (depends on 55)

The method of claim 55, wherein the step of detecting comprises a lateral flow assay or an enzyme-linked immunoassay, wherein the enzyme-linked immunoassay is an ELISA.

### Claim 57

A method of identifying an Ehrlichia infection in a mammalian subject comprising: (a) contacting a biological sample from the subject with an isolated polypeptide of Ecaj_0919, Ecaj_0073, Ecaj_0104, Ecaj_0663, or Ecaj_0881, more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, or Ecaj_0663, even more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, even more preferably Ecaj_0919 or Ecaj_0073, under conditions that allow peptide-antibody complexes to form; and (b) detecting the peptide-antibody complexes; wherein the detection of the peptide-antibody complexes is an indication that the subject has an Ehrlichia infection.

### Claim 58 (depends on 57)

The method of claim 57, wherein the step of detecting comprises performing an enzyme-linked immunoassay, a radioimmunoassay, an immunoprecipitation, a fluorescence immunoassay, a chemiluminescent assay, an immunoblot assay, a lateral flow assay, a flow cytometry assay, a multiplex immunoassay, a dipstick test, or a particulate-based assay.

### Claim 59 (depends on 57, 58)

The method of any one of claims 57-58, wherein the subject is a dog.

### Claim 60

An isolated polypeptide comprising a sequence of Ecaj_0919, Ecaj_0073, Ecaj_0104, Ecaj_0663, or Ecaj_0881, more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, or Ecaj_0663, even more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, even more preferably Ecaj_0919 or Ecaj_0073, wherein the isolated peptide is immobilized on a surface of a support substrate.

### Claim 61 (depends on 60)

The peptide of claim 60, wherein the support substrate comprises latex, polystyrene, nylon, nitrocellulose, cellulose, silica, agarose, or magnetic resin.

### Claim 62 (depends on 60, 61)

The peptide of any one of claims 60-61, wherein the support substrate is a reaction chamber, a well, a membrane, a filter, a paper, an emulsion, a bead, a microbead, a dipstick, a card, a glass slide, a lateral flow apparatus, a microchip, a comb, a silica particle, a magnetic particle, a nanoparticle, or a self-assembling monolayer.

### Claim 63 (depends on 60, 61, 62)

The peptide of any one of claims 60-62, wherein the peptide is comprised in a kit.

### Claim 64 (depends on 60, 61, 62)

The peptide of any one of claims 60-62, wherein the peptide is produced via peptide synthesis or in vitro transcription and translation (IVTT).

### Claim 65 (depends on 60, 61, 62)

The peptide of any one of claims 60-62, wherein the peptide is recombinantly produced.

### Claim 66

An isolated polypeptide comprising a sequence of Ecaj_0919, Ecaj_0073, Ecaj_0104, Ecaj_0663, or Ecaj_0881, more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, or Ecaj_0663, even more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, even more preferably Ecaj_0919 or Ecaj_0073, wherein the isolated peptide is covalently attached to a detectable label.

### Claim 67 (depends on 66)

The polypeptide of claim 66, wherein the detectable label a fluorescent label, a radioactive label, an enzyme label, or a luminescent nanoparticle.

### Claim 68 (depends on 67)

The polypeptide of claim 67, wherein the luminescent nanoparticle is a luminescent rare earth nanoparticle, a luminous nanoparticle, or a strontium aluminate nanoparticle.

### Claim 69 (depends on 66, 67, 68)

The polypeptide of any one of claims 66-68, wherein the polypeptide is comprised in a kit.

### Claim 70 (depends on 66, 67, 68, 69)

The polypeptide of any one of claims 66-69, wherein the polypeptide is produced via peptide synthesis or in vitro transcription and translation (IVTT).

### Claim 71 (depends on 66, 67, 68, 69)

The polypeptide of any one of claims 66-69, wherein the polypeptide is recombinantly produced.

### Claim 72 (depends on 66, 67, 68, 69, 70, 71)

A kit comprising: (a) the isolated polypeptide of any one of claims 66-71, (b) an anti-dog or anti-human secondary antibody linked to a reporter molecule; and, (c) an appropriate reagent for detection of the reporter molecule.

### Claim 73 (depends on 72)

The kit of claim 72, wherein the peptide is immobilized on a membrane or a microtiter plate.

### Claim 74 (depends on 72, 73)

The kit of any one of claims 72-73, wherein the reporter molecule is selected from the group consisting of luciferase, horseradish peroxidase, a luminous nanoparticle, P-galactosidase, and a fluorescent label.

### Claim 75 (depends on 74)

The kit of claim 74, wherein the luminous nanoparticle is a strontium aluminate nanoparticle.

### Claim 76 (depends on 72, 73, 74, 75)

The kit of claim of any one of claims 72-75, wherein the kit further comprises a dilution buffer for dog or human serum.

### Claim 77 (depends on 72, 73, 74, 75, 76)

The kit of claim of any one of claims 72-76, wherein the kit comprises a lateral flow immunoassay or a lateral flow immunochromatographic assay.

### Claim 78 (depends on 72, 73, 74, 75, 76, 77)

The kit of claim of any one of claims 72-77, wherein the kit comprises an enzyme-linked immunosorbent assay (ELISA).

### Claim 79

A method of inducing an immune response in a mammalian subject comprising administering to the subject an effective amount of a pharmaceutical preparation comprising a polypeptide of Ecaj_0919, Ecaj_0073, Ecaj_0104, Ecaj_0663, or Ecaj_0881, more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, or Ecaj_0663, even more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, even more preferably Ecaj_0919 or Ecaj_0073.

### Claim 80 (depends on 79)

The method of claim 79, wherein the subject is a human.

### Claim 81 (depends on 79, 80)

The method of any one of claims 79-80, wherein the pharmaceutical preparation is administered subcutaneously, intramuscularly, nasally, via inhalation or aerosol delivery, or intradermally.

### Claim 82

A method of treating an Ehrlichia canis infection in a mammalian subject comprising:
(a) contacting a biological sample from the subject with an isolated polypeptide of Ecaj_0919, Ecaj_0073, Ecaj_0104, Ecaj_0663, or Ecaj_0881, more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, or Ecaj_0663, even more preferably Ecaj_0919, Ecaj_0073, Ecaj_0104, even more preferably Ecaj_0919 or Ecaj_0073, under conditions that allow peptide-antibody complexes to form;
(b) detecting the peptide-antibody complexes; wherein the detection of the peptide-antibody complexes is an indication that the subject has an Ehrlichia canis infection; and
(c) administering a therapeutic compound to treat Ehrlichia infection in the subject.

### Claim 83 (depends on 82)

The method of claim 82, wherein the step of detecting comprises performing an enzyme-linked immunoassay, a radioimmunoassay, an immunoprecipitation, a fluorescence immunoassay, a chemiluminescent assay, an immunoblot assay, a lateral flow assay, a flow cytometry assay, a multiplex immunoassay, a dipstick test, or a particulate-based assay.

### Claim 84 (depends on 82)

The method of claim 82, wherein the subject is a dog.

### Claim 85 (depends on 82, 83, 84)

The method of any one of claims 82-84, wherein the therapeutic compound is an antibiotic.

### Claim 86 (depends on 85)

The method of claim 85, wherein the antibiotic is doxycycline.
